Although many studies have demonstrated that HDACis enhance the anti-tumor response of NK cells by upregulating NKG2D, the results of a recent study suggest that HDACis may down-regulate another activating ligand, B7-H6, thereby inhibiting NK cell-mediated tumor cell recognition (160). Here, NCR3LG1 is linked to neoplasm.